July 1, 2021



News
January 11, 2021
Navrogen Establishes Research Collaboration with The National Cancer Institute to Test Mesothelin-Targeting Therapies for Cancers Affected by Humoral Immuno-Oncology Factors
September 29, 2020
Navrogen Signs Commercial License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immuno-suppressed Cancers
September 14, 2020
Navrogen Awarded National Cancer Institute Grant to Develop Next-Generation Rituximab with Enhanced Therapeutic Effects
February 4, 2020
Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates to Treat Humoral Immuno-Suppressed Cancers
January 31, 2020